Celldex Therapeutics, Inc. (CLDX) Cash Flow Statement
Celldex Therapeutics, Inc. (CLDX) generated -$235.6M of operating cash flow over the twelve months to 2026-06-30, spent $6.5M on capital expenditure and had free cash flow of -$242.1M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CLDXCelldex Therapeutics, Inc.Follow CLDX — free
—
Price chart with a free account
- Market cap
- 2.3B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -35.7 | -49.8 | -67.7 | -101.5 | -98.9 | -113.0 | -99.9 | -75.2 | -46.4 | -40.4 | -60.9 | -103.7 | -107.3 | -157.8 | -210.9 | -235.6 | |
| Capital expenditure | 0.5 | 0.3 | 4.2 | 1.9 | 4.9 | 2.8 | 1.8 | 0.8 | 0.7 | 1.6 | 1.2 | 1.8 | 1.8 | 1.9 | 2.7 | -6.5 | |
| Free cash flow | -36.2 | -50.1 | -71.9 | -103.5 | -103.8 | -115.8 | -101.7 | -76.0 | -47.1 | -42.0 | -62.2 | -105.6 | -109.1 | -159.7 | -213.7 | -242.1 | |
| Stock-based compensation | 2.3 | 2.3 | 4.5 | 6.9 | 12.8 | 15.3 | 12.3 | 8.1 | 4.6 | 3.9 | 9.0 | 15.6 | 23.9 | 34.2 | 36.2 | — |
USD millions · SEC XBRL
Celldex Therapeutics, Inc. — questions
- What is Celldex Therapeutics, Inc.'s operating cash flow?
- -$235.6M over the twelve months to 2026-06-30.
- How much does Celldex Therapeutics, Inc. spend on capital expenditure?
- $6.5M over the twelve months to 2026-06-30.
- What is Celldex Therapeutics, Inc.'s free cash flow?
- -$242.1M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Celldex Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.